MPR for Stroke Risk Assessment of ICAS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorXuanwu Hospital, Beijing
About this trial
Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 to 80 years.
Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.
Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.
Written informed consent obtained from the participant or a legal representative.
Disqualifiers
Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities.
More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.
Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.
Contraindications to antiplatelet therapy or statins.
Trial population
Patients with ICAS involving 50% to 99% stenosis of a major intracranial artery in the anterior circulation, including the internal carotid artery (ICA C6-C7 segment) and the middle cerebral artery M1 (MCA-M1) segment.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Standardized medical therapy targeting vascular risk factors and stroke prevention
DrugDual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines
Treatment groups
400 Participants
are divided into 1 treatment groupGroup A: CASSISS-MPR1 intervention
Trial outcomes
Primary outcomes
1
ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.
the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.
Time frame
12 monthsSecondary outcomes
1
transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year
the number of participants who suffer from transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year after enrollment.
Time frame
12 months2
TIA related to ischemia in the qualifying artery territory within 1 year
the number of participants who suffer from TIA related to ischemia in the qualifying artery territory within 1 year
Time frame
12 months3
any stroke/TIA/ death within 1 year
the number of participants who suffer from any stroke/TIA/ death within 1 year
Time frame
12 months4
hemodynamic ischemic stroke in the qualifying artery territory within 1 year
the number of participants who suffer from hemodynamic ischemic stroke in the qualifying artery territory within 1 year
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Xuanwu Hospital, Beijing
Lead sponsor
Xuanwu Hebei Hospital
Collaborator
Xuanwu Xiongan Hospital
Collaborator
Xuanwu Chifeng Hospital
Collaborator
Xuanwu Jinan Hospital
Collaborator
Source ClinicalTrials.gov